Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionPharmacogenetic test that predicts response to rituximab monotherapy
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics: Biomarkers and companion diagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsPredict response to rituximab therapy in follicular non-Hodgkin's lymphoma (NHL) patients
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today